comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Comparative effectiveness of versus receptor on cardiovascular– kidney–metabolic stage progression: a real-world cohort study It's important to study the – Impact of GLP-1 receptor agonists

Important considerations for calculating your protein needs: Use ideal or adjusted body weight rather than current weight for calculations Distribute protein across multiple meals (0.25-0.4 g/kg per meal) Prioritize protein intake early in the day when appetite may be better If you have chronic kidney disease (CKD stage 3 or higher), follow ADA/KDIGO guidelines of approximately 0.8 g/kg/day unless otherwise directed by your nephrologist Work with a registered dietitian for personalized recommendations These targets aim to preserve lean muscle mass, support metabolic rate, and optimize body composition changes during weight loss

Biochem Biophys Res Commun 272 : 182185

What we are seeing now: Accelerated process optimization and cost-down strategies Early CDMO partnerships and backward integration Increasing focus on key fragments, side chains, and impurity control, not just the final API The question is no longer if generics will enter the market, but who will be ready when the window truly opens

Glucagon-Like-Peptide 1 (GLP-1)

doi:10.1038/ncb3064